Early Phase II Trials for Cocaine Medication Development - 1
Cocaine-Related Disorders, Substance-Related Disorders
About this trial
This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring Cocaine, METHADONE PATIENTS, RISPERIDONE
Eligibility Criteria
Inclusion: good standing at methadone maintenance program DSM-IV criteria for cocaine dependence or abuse used cocaine at least 4 times in last month able to give informed consent Exclusion criteria currently meets DSM-IV criteria for Major depression or dysthymia meets DSM-IV criteria for attention deficit hyperactivity disorder, bipolar disorder, schizophrenia or any psychotic disorder history of seizures history of allergic reaction to risperidone chronic organic mental disorder significant current suicidal risk pregnancy, lactation or failure to use adequate birth control (for females) unstable physical disorders that may make participation hazardous coronary vascular disease cardiac conduction system disease as indicated by QRS duration >/= 0.11 current use of other prescribed psychotropic medications history of failure to respond to a previous adequate trial of risperidone history of neuroleptic malignant syndrome, tardive dyskinesia, or severe extrapyramidal reactions to neuroleptic medications current DSM-IV criteria for another substance dependence other than nicotine.
Sites / Locations
- NYS Psychiatric Institute
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
PLacebo
Risperidone
Placebo plus relapse prevention counseling
Risperidone (4mg/day) plus relapse prevention counseling